Boryung eying sales of 10 billion won with new drug
Published: 2011-09-19 06:58:00
Updated: 2011-09-19 06:58:00
Boryung Pharmaceutical Co. says its new drug for hypertension “Kanarb (fimasartan)”, angiotensin II receptor antagonist with a selective AT1 receptor blockade effect, is expected to achieve a 10 billion won in sales within one year since its launch in March.
Such robust sales will be possible ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.